DO PREDICTORS OF IV ABATACEPT RETENTION DEPEND ON THE LINE OF RHEUMATOID ARTHRITIS TREATMENT: 12-MONTH INTERIM ANALYSIS OF THE OBSERVATIONAL, PROSPECTIVE ACTION STUDY

被引：2

作者：

Alten, R. ^{[1
]}

Nuesslein, H. ^{[2
]}

Galeazzi, M. ^{[3
]}

Lorenz, H. M. ^{[4
]}

Mariette, X. ^{[5
]}

Cantagrel, A. ^{[6
]}

Chartier, M. ^{[7
]}

Elbez, Y. ^{[8
]}

Rauch, C. ^{[9
]}

Le Bars, M. ^{[10
]}

机构：

[1] Schlosspk Klin Univ Med, Berlin, Germany

[2] Univ Erlangen Nurnberg, Nurnberg, Germany

[3] Univ Siena, Siena, Italy

[4] Univ Hosp, Heidelberg, Germany

[5] Univ Paris Sud, Paris, France

[6] Hop Purpan, Toulouse, France

[7] Chiltern Int, Neuilly, France

[8] Excelya, Boulogne, France

[9] Bristol Myers Squibb, Munich, Germany

[10] Bristol Myers Squibb, Rueil Malmaison, France

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷

关键词：

D O I：

10.1136/annrheumdis-2016-eular.1289

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0066

引用

页码：202 / 202

页数：1

共 1 条

[1] Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study [J].

Nuesslein, Hubert G. ;

Alten, Rieke ;

Galeazzi, Mauro ;

Lorenz, Hanns-Martin ;

Nurmohamed, Michael T. ;

Bensen, William G. ;

Burmester, Gerd R. ;

Peter, Hans-Hartmut ;

Pavelka, Karel ;

Chartier, Melanie ;

Poncet, Coralie ;

Rauch, Christiane ;

Le Bars, Manuela .

BMC MUSCULOSKELETAL DISORDERS, 2015, 16

← 1 →